Prolactinoma: A condition associated with hypoadiponectinemia

Hormone and Metabolic Research

Volumn 44, Issue 11, 2012, Pages 832-838

  De Assuncao Alves Rodrigues L F ^a   Campos, S M S ^a   Miranda, P A C ^a   Bizzi, M F ^a   Sales Do Amaral, P H ^a   Giannetti, A V ^a   Ribeiro Oliveira, A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

adiponectin; HOMAIR; hyperlipidemia; insulin resistance; prolactin

Indexed keywords

ADIPONECTIN; BROMOCRIPTINE; CABERGOLINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; TRIACYLGLYCEROL;

ADULT; AGE; ANALYTIC METHOD; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS ASSESSMENT MODEL OF INSULIN RESISTANCE; HORMONE BLOOD LEVEL; HUMAN; HYPOADIPONECTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLISM, INBORN ERRORS; PITUITARY NEOPLASMS; PROLACTINOMA; TRIGLYCERIDES;

EID: 84867329018     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1321832     Document Type: Article

References (35)

1. Freeman M., Kanyicska B., Lerant A., Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev: 2000; 80 1523 1631
2. Melmed S., Casanueva F. F., Hoffman A. R., Kleinberg D. L., Montori V. M., Schlechte J. A., Wass J. A. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab: 2011; 96 273 288
3. Reis F. M., Ribeiro-de-Oliveira A., Guerra R. M., Reis A. M., Coimbra C. C. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sci: 1996; 58 155 161
4. Schmid C., Goede D., Hauser R., Brändle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Weekly: 2006; 136 254 258
5. Yavuz D., Deyneli O., Akpinar I., Yildiz E., Gözü H., Sezgin O., Haklar G., Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol: 2003; 149 187 193
6. Reuwer A. Q., van Zaane B., van Wissen M., van Zanten A. P., Twickler M. T., Gerdes V. E. Prolactin is involved in the systemic inflammatory response in myocardial infarction. Horm Metab Res: 2011; 43 62 65
7. dos Santos Silva C. M., Barbosa F. R., Lima G. A., Warszawski L., Fontes R., Domingues R. C., Gadelha M. R. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring): 2011; 19 800 805
8. Cincotta A. H., Meier A. H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care: 1996; 19 667 670
9. Berinder K., Nyström T., Höybye C., Hall K., Hulting A. L. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary: 2011; 14 199 207
10. Halleux C. M., Takahashi M., Delporte M. L., Detry R., Funahashi T., Matsuzawa Y., Brichard S. M. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun: 2001; 288 1102 1107
11. Delporte M. L., Funahashi T., Takahashi M., Matsuzawa Y., Brichard S. M. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J: 2002; 367 677 685
12. Krakoff J., Funahashi T., Stehouwer C. D., Schalkwijk C. G., Tanaka S., Matsuzawa Y., Kobes S., Tataranni P. A., Hanson R. L., Knowler W. C., Lindsay R. S. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care: 2003; 26 1745 1751
13. Fruebis J., Tsao T., Javorschi S., Ebbets-Reed D., Erickson M., Yen F., Bihain B., Lodish H. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A: 2001; 98 2005 2010
14. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med: 2002; 8 1288 1295
15. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R., Tataranni P. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab: 2001; 86 1930 1935
16. Nilsson L., Binart N., Bohlooly-Y M., Bramnert M., Egecioglu E., Kindblom J., Kelly P., Kopchick J., Ormandy C., Ling C., Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun: 2005; 331 1120 1126
17. Asai-Sato M., Okamoto M., Endo M., Yoshida H., Murase M., Ikeda M., Sakakibara H., Takahashi T., Hirahara F. Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes. Endocr J: 2006; 53 555 562
18. Fuglsang J., Skjaerbaek C., Frystyk J., Flyvbjerg A., Ovesen P. A longitudinal study of serum adiponectin during normal pregnancy. BJOG: 2006; 113 110 113
19. Geloneze B., Repetto E., Geloneze S., Tambascia M., Ermetice M. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract: 2006; 72 219 220
20. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA: 2001; 285 2486 2497
21. DeFronzo R. A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care: 1991; 14 173 194
22. Kyriazi E., Tsiotra P. C., Boutati E., Ikonomidis I., Fountoulaki K., Maratou E., Lekakis J., Dimitriadis G., Kremastinos D. T., Raptis S. A. Effects of adiponectin in TNF-α, IL-6, and IL-10 cytokine production from coronary artery disease macrophages. Horm Metab Res: 2011; 43 537 544
23. Delgrange E., Donckier J., Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxf): 1999; 50 271
24. Baptista T., Lacruz A., Meza T., Contreras Q., Delgado C., Mejìas M., Hernàndez L. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry: 2001; 46 829 834
25. Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf): 1998; 48 547 553
26. Ling C., Svensson L., Odén B., Weijdegård B., Edén B., Edén S., Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab: 2003; 88 1804 1808
27. Tuzcu A., Yalaki S., Arikan S., Gokalp D., Bahcec M., Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary: 2009; 12 330 334
28. Galsgaard E. D., Nielsen J. H., Moldrup A. Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells. Prolactin and growth hormone activate one of the rat prlr gene promoters via STAT5a and STAT5b. J Biol Chem: 1999; 274 18686 18692
29. Schernthaner G., Prager R., Punzengruber C., Luger A. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia: 1985; 28 138 142
30. Defronzo R. A. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care: 2011; 34 789 794
31. Ribeiro-de-Oliveira A., Guerra R. M., Fóscolo R. B., Marubayashi U., Reis A. M., Coimbra C. C. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol: 1999; 162 237 242
32. Combs T. P., Berg A. H., Rajala M. W., Klebanov S., Iyengar P., Jimenez-Chillaron J. C., Patti M. E., Klein S. L., Weinstein R. S., Scherer P. E. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes: 2003; 52 268 276
33. Shen W., Wang Z., Punyanita M., Lei J., Sinav A., Kral J. G., Imielinska C., Ross R., Heymsfield S. B. Adipose tissue quantification by imaging methods: a proposed classification. Obes Res: 2003; 11 5 16
34. Hoenig M. R. MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort. Vasc Health Risk Manag: 2010; 6 629 633
35. Hattori Y., Hattori S., Akimoto K., Nishikimi T., Suzuki K., Matsuoka H., Kasai K. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes: 2007; 56 804 808